Aethlon Medical, Inc. (Aethlon) is a developmental-stage company focused on creating medical devices that address infectious disease and cancer. The Company is engaged in the research and development of a medical device known as the Hemopurifier that removes harmful substances from the blood. Hemopurifier selectively targets the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. Hemopurifier also captures tumor-secreted exosomes, known to kill off the immune cells of those afflicted with cancer. Aethlon has submitted an Investigational Device Exemption (IDE) to the United States Food and Drug Administration (FDA). In December 2009, Aethlon formed Exosome Sciences, Inc. to conduct its cancer-related activities. Effective November 25, 2009, the Company dissolved its dormant subsidiaries, Hemex, Inc., Aethlon, Inc., Syngen Research, Inc. and Cell Activation, Inc.